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A BS TR AC T
BACKGROUND
Linezolid has antimycobacterial activity in vitro and is increasingly used for patients 
with highly drug-resistant tuberculosis.
METHODS
We enrolled 41 patients who had sputum-culture–positive extensively drug-resistant 
(XDR) tuberculosis and who had not had a response to any available chemotherapeu-
tic option during the previous 6 months. Patients were randomly assigned to linez-
olid therapy that started immediately or after 2 months, at a dose of 600 mg per 
day, without a change in their background regimen. The primary end point was the 
time to sputum-culture conversion on solid medium, with data censored 4 months 
after study entry. After confirmed sputum-smear conversion or 4 months (which-
ever came first), patients underwent a second randomization to continued linezolid 
therapy at a dose of 600 mg per day or 300 mg per day for at least an additional 
18 months, with careful toxicity monitoring.
RESULTS
By 4 months, 15 of the 19 patients (79%) in the immediate-start group and 7 of the 
20 (35%) in the delayed-start group had culture conversion (P = 0.001). Most patients 
(34 of 39 [87%]) had a negative sputum culture within 6 months after linezolid had 
been added to their drug regimen. Of the 38 patients with exposure to linezolid, 31 
(82%) had clinically significant adverse events that were possibly or probably related 
to linezolid, including 3 patients who discontinued therapy. Patients who received 
300 mg per day after the second randomization had fewer adverse events than those 
who continued taking 600 mg per day. Thirteen patients completed therapy and have 
not had a relapse. Four cases of acquired resistance to linezolid have been observed.
CONCLUSIONS
Linezolid is effective at achieving culture conversion among patients with treatment-
refractory XDR pulmonary tuberculosis, but patients must be monitored carefully for 
adverse events. (Funded by the National Institute of Allergy and Infectious Diseases 
and the Ministry of Health and Welfare, South Korea; ClinicalTrials.gov number, 
NCT00727844.)
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Linezolid (Zyvox, Pfizer) was approved in 2000 for drug-resistant, gram-positive bac-terial infections.1 A member of the oxazolid-
inone antibiotic class, linezolid inhibits protein 
synthesis by binding the 23S ribosomal RNA 
(rRNA) portion of the bacterial 50S ribosomal 
subunit.2 In adults, linezolid is administered at a 
dose of 600 mg twice daily, with phase 3 and 
postmarketing trials showing an acceptable side-
effect and adverse-event profile during the FDA-
approved 28 days of therapy.3 Data on longer-term 
use are limited, but serious neuropathies (e.g., pe-
ripheral and optic neuropathies), myelosuppres-
sion, and hyperlactatemia have been observed4,5 
and are considered to be related to the inhibition 
of mitochondrial protein synthesis.6,7
Linezolid exhibits in vitro bacteriostatic ac-
tivity against Mycobacterium tuberculosis, including 
multidrug-resistant (MDR) and extensively drug-
resistant (XDR) strains, with a minimum inhibi-
tory concentration of less than 1 μg per millili-
ter.8-11 It has only modest activity in murine 
models of tuberculosis.12,13 A study of the early 
and extended bactericidal activity of linezolid 
showed only minimal early activity (during the 
initial 2 days) and no late activity (during the sub-
sequent 5 days), with the authors concluding that 
linezolid had little tissue-sterilizing ability and 
therefore had a limited role in the treatment of 
MDR tuberculosis.14 Despite these characteristics, 
a number of case reports and retrospective studies 
suggest that linezolid may be effective in treating 
MDR and XDR tuberculosis.15-21 These studies 
all have important limitations, including a retro-
spective design, small numbers, the use of linez-
olid with multiple other active agents, no controls, 
and limited follow-up. This apparent discrepancy 
between preclinical data and clinical observations 
prompted us to undertake a prospective, random-
ized trial of linezolid in patients with chronic XDR 
tuberculosis who did not have a response to all 
other available chemotherapeutic options.
ME THODS
STUDY PATIENTS
From December 2008 through May 2011, we en-
rolled adults, 20 years of age or older, with chron-
ic XDR pulmonary tuberculosis (positive sputum 
smear and culture) and with confirmed genotypic 
or phenotypic resistance to isoniazid, rifampin, 
kanamycin, ofloxacin, and moxifloxacin or a doc-
umented nonresponse to treatment, despite test 
results showing drug susceptibility. Patients were 
eligible if they had been treated with an un-
changed, failing regimen for 6 months or more 
before enrollment. Exclusion criteria were previ-
ous treatment with linezolid, anticipated surgical 
treatment, a positive test result for the human 
immunodeficiency virus (HIV), specific baseline 
laboratory abnormalities, moderate-to-severe pe-
ripheral or optic neuropathy, and need for treat-
ment with contraindicated drugs. Additional 
details regarding the inclusion and exclusion cri-
teria, regimen changes, dose adjustments, study 
timeline, and adverse events are provided in the 
Supplementary Appendix and the study protocol, 
both of which are available with the full text of 
this article at NEJM.org.
STUDY DESIGN AND OUTCOME MEASURES
This phase 2a, randomized, two-group study was 
conducted at the National Masan Hospital in 
Changwon and the National Medical Center in 
Seoul, South Korea. Patients were randomly as-
signed to receive linezolid, at a dose of 600 mg per 
day, in addition to their existing regimen, either 
immediately or after a 2-month delay. Permuted-
block randomization was performed, with strati-
fication according to status with regard to diabe-
tes mellitus (types 1 and 2 included). A 2-month 
delay was used to minimize the possibility that 
study effects other than linezolid could account 
for observed improvement. All patients continued 
their existing regimen and were hospitalized from 
the time of enrollment until sputum-culture con-
version. The microbiology staff were unaware of 
treatment assignments throughout the study.
The primary end point was sputum-culture 
conversion, with data censored at 4 months. Con-
version was defined as negative sputum samples 
on solid (Löwenstein–Jensen) medium for 3 con-
secutive weeks; culture on liquid medium was 
performed with the use of the MB/BacT auto-
mated mycobacterial culture system. Patients con-
tinued taking linezolid at a dose of 600 mg per 
day until they had negative sputum smears (Ziehl–
Neelsen staining) for 2 consecutive weeks or until 
they had received 4 months of linezolid treat-
ment, whichever came first. Regimen changes, 
which were not allowed during the 6 months 
before enrollment, were allowed after sputum-
smear conversion and at least 2 months of treat-
ment with linezolid. After conversion to negative 
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sputum smears (or receipt of 4 months of thera-
py), patients underwent a second randomization, 
stratified according to diabetes mellitus status, 
either to continue receiving linezolid at a dose of 
600 mg per day or to receive a lower dose, 300 mg 
per day, for an additional 18 months or until 
therapy was stopped owing to side effects or 
laboratory abnormalities.
If adverse events occurred that were consid-
ered to be related to linezolid, a reduction in the 
dose or a rechallenge at a dose of 300 mg per day 
was allowed after a limited drug holiday (described 
in Table 2 in the Supplementary Appendix). Lin-
ez olid was administered by means of directly 
observed therapy during hospitalization. The study 
staff monitored outpatient adherence by means 
of videophone or telephone every weekday and also 
performed pill counts monthly. Patients were 
treated for at least 18 months after sputum-culture 
conversion and were followed for an additional 
12 months after completing the treatment. Blood 
was collected for pharmacokinetic analysis22 of 
linezolid at both doses.
ADVERSE-EVENT MONITORING
Patients underwent baseline and serial safety 
evaluations (including complete blood counts, 
blood chemical measurements, and liver-function 
tests) weekly until 16 weeks, every 2 weeks from 
17 through 24 weeks, and then monthly thereaf-
ter. A neurologist evaluated all patients at entry 
with the use of nerve-conduction studies and was 
available for repeat consultation if any peripheral 
neuropathy developed. The Subjective Peripheral 
Neuropathy Screen, a screening tool used in the 
treatment of HIV infection (Supplementary Mate-
rial 2 in the Supplementary Appendix),23 and clin-
ical neurologic examinations were performed by 
the study staff at baseline and monthly thereafter. 
To monitor patients for linezolid-induced optic 
neuropathy, the study staff performed testing for 
visual acuity (using the Han test, which is similar 
to the Snellen chart), contrast sensitivity, and color 
vision (using Ishihara plates). Patients with any 
symptoms or abnormal findings were referred to 
an ophthalmologist.
STUDY OVERSIGHT
Written informed consent was obtained from all 
participants. The study was approved by the local 
institutional review boards and by the U.S. National 
Institute of Allergy and Infectious Diseases and was 
conducted in accordance with Good Clinical Prac-
tice guidelines. A data and safety monitoring board 
reviewed adverse events and provided management 
guidance to investigators. All serious adverse events 
were reported to the data and safety monitoring 
board, all institutional review boards, and the U.S. 
and Korean Food and Drug Administrations, per 
protocol. The study was monitored by an indepen-
dent clinical research organization. Pfizer provided 
linezolid at no cost and reviewed the protocol with-
out comment. The authors are fully responsible 
for the study design, data collection, analysis, com-
pleteness of data reporting, fidelity of this report to 
the study protocol, and interpretation of the data.
STATISTICAL ANALYSIS
From prior case studies, we estimated a culture-
conversion rate of more than 90% with linezolid 
during the first 4 months of therapy, and on the 
basis of historical data, we assumed that less than 
10% of patients would have spontaneous culture 
conversion without having received linezolid. 
Thus, we calculated that a sample of 16 patients 
per group would provide 92% power, assuming a 
two-sided type 1 error rate of 0.05 and a 10% dis-
continuation rate. We planned to recruit 20 pa-
tients per group to allow for additional loss to 
follow-up and death. For the primary analysis of 
time to culture conversion on solid medium, we 
used a generalized Wilcoxon test24 and a modified 
intention-to-treat analysis, which excluded 2 pa-
tients who withdrew (owing to baseline neuropa-
thy) before receiving any linezolid. Data from 
other patients who withdrew were included in 
the modified intention-to-treat analysis as treat-
ment failures. Ethical concerns regarding the 
delayed-start group prompted the data and safety 
monitoring board to request two unplanned in-
terim analyses: one when 16 patients had an end 
point that could be evaluated and one when 32 had 
such an end point. For the interim analysis of the 
primary end point, the Haybittle–Peto rule was 
used, which specifies a strict significance level of 
0.001 as the criterion for stopping the study early 
because of efficacy and allows for the usual 0.05 
level of significance at the final analysis.25 The 
boundary for early stopping was not met, and 
follow-up of the 39 patients in the modified 
intention-to-treat cohort continued until the 
planned stopping point.
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R ESULT S
STUDY PATIENTS
A total of 41 patients underwent randomization, 
with 21 assigned to the immediate-start group and 
20 to the delayed-start group (Fig. 1). Owing to pre-
existing neuropathy, 2 patients in the immediate-
start group were withdrawn from the study before 
receiving any dose of linezolid and were excluded 
from the modified intention-to-treat analysis. The 
remaining 39 patients were predominantly men 
(72%), with a mean age of 41.2 years (range, 20 to 
64), and 36% of the patients had diabetes mellitus 
(Table 1). On the basis of radiologic testing, 77% 
of the patients were classified as having “far ad-
vanced” tuberculosis, which was defined accord-
ing to the guidelines of the Korea Centers for Dis-
ease Control and Prevention26 as the presence of 
disseminated lesions of slight-to-moderate density 
exceeding the total volume of one lung, or dense 
and confluent lesions exceeding one third the vol-
ume of one lung, or the presence of cavities great-
er than 4 cm in diameter. Patients had a median of 
5 previous treatment episodes for pulmonary tuber-
culosis (interquartile range, 3 to 8), and their iso-
lates were resistant to a mean of 11 drugs (range, 
6 to 15). The baseline characteristics reported in 
Table 1 were well balanced between the two 
groups.
PRIMARY OUTCOME
The primary outcome was the time to sputum-
culture conversion, with data censored at 4 months. 
By 4 months, 15 of the 19 patients (79%) in the 
immediate-start group and 7 of the 20 (35%) in the 
delayed-start group had conversion to negative spu-
tum cultures on solid medium (P = 0.001) (Fig. 2A). 
Although culture conversion on solid medium is 
historically the standard used to gauge the effec-
tiveness of a treatment, we also monitored culture 
results on liquid medium. With data censored at 
4 months, 12 of the 19 patients (63%) in the im-
mediate-start group and 11 of the 20 (55%) in the 
delayed-start group had culture conversion on liq-
uid medium (P = 0.07) (Fig. 2B). Liquid culture me-
dium is thought to have higher sensitivity and more 
reproducible results than solid-culture medium.27 
In our study, however, the culture results on liq-
uid medium had only borderline significance at 
the per-protocol censored time point (4 months), 
owing to the higher-than-expected rate of conver-
sion to negative cultures on liquid medium in the 
delayed-start group.
Combining the two groups, we observed that 
34 of the 38 patients who received linezolid 
(89%) had culture conversion on solid medium by 
6 months (Fig. 2C), at a median of 75 days after 
the start of treatment with linezolid. One patient 
withdrew before receiving the study drug, owing to 
a diagnosis of metastatic colon cancer; data from 
this person were included in the modified inten-
tion-to-treat analysis as a treatment failure. As of 
May 1, 2012, of the 38 patients who received lin-
ezolid, 17 were still receiving the treatment per 
protocol, and 13 had completed treatment, includ-
ing 6 with no relapse during the treatment period, 
4 with no relapse at the 6-month follow-up, and 
3 with no relapse at the 12-month follow-up (end 
of study). Eight patients withdrew early: 4 patients 
owing to treatment failure, 1 for personal reasons, 
and 3 owing to adverse events (Fig. 4 in the Sup-
plementary Appendix).
SAFETY
Of the 38 patients who received linezolid, 33 (87%) 
had clinically significant adverse events; 31 pa-
tients (82%) had events that were possibly or 
probably related to linezolid (Table 2 in the Sup-
plementary Appendix). Most adverse events re-
solved relatively quickly, and only 3 patients per-
manently discontinued linezolid owing to drug 
toxicity (2 patients because of optic neuropathy, and 
1 because of anemia). We observed seven episodes 
of myelosuppression, including anemia and neutro-
penia, which occurred primarily within the first 
5 months (Fig. 3A, and Table 3 in the Supplemen-
tary Appendix). In addition, we observed 7 cases 
of optic neuropathy, 21 cases of peripheral neu-
ropathy, and 1 case of rhabdomyolysis,28 with 
these events occurring during the first year of 
treatment.
Of the 38 patients who received linezolid, 33 
(87%) underwent the scheduled second random-
ization (1 patient had an adverse event requiring 
withdrawal from the study and 4 had an adverse 
event requiring dose reduction before undergoing 
this randomization) (Fig. 1). In the second ran-
domization, 17 patients were assigned to con-
tinue receiving the 600-mg daily dose, and 16 to 
receive 300 mg per day. Of the 17 patients who 
continued taking 600 mg per day, 15 (88%) had 
an adverse event related to the study drug, with 
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41 Underwent randomization
50 Patients underwent screening
9 Were excluded
6 Were excluded
2 Were withdrawn before
receiving any linezolid owing
to baseline neuropathy
19 Were included in the analysis 20 Were included in the analysis
33 Underwent second randomization
17 Were assigned to continue receiving
600 mg of linezolid daily
16 Were assigned to receive
300 mg of linezolid daily
17 Were included in the analysis 16 Were included in the analysis
21 Were assigned to immediate treatment 
with 600 mg of linezolid daily
20 Were assigned to delayed treatment 
(2-mo delay) with 600 mg of linezolid daily
Figure 1. Enrollment, Randomization, and Follow-Up of the Study Patients.
Between December 2008 and May 2011, a total of 50 patients were screened for eligibility and 41 underwent random-
ization. Two patients were subsequently withdrawn owing to preexisting peripheral neuropathy that was discovered 
during the baseline examination; the remaining 39 patients were included in the modified intention-to-treat analysis. 
Two other patients who withdrew before culture conversion were considered to have treatment failure: 1 patient, who 
had an adverse event requiring a drug holiday, was withdrawn 79 days after starting treatment with linezolid because 
the drug holiday exceeded the protocol-specified window (28 days before sputum-culture conversion and 42 days  
after sputum-culture conversion); the other patient was withdrawn 32 days after study entry because of a diagnosis 
of advanced colon cancer (this patient was in the delayed-start group and had not received any linezolid). Thirty-three 
patients underwent the second randomization; 17 patients were randomly assigned to continue receiving linezolid 
at a dose of 600 mg per day, and 16 to receive the reduced dose of 300 mg per day. The 6 patients who did not un-
dergo the second randomization included 4 who had dose reductions due to adverse events before culture conver-
sion and the 2 withdrawn patients mentioned above who were included in the modified intention-to-treat analysis 
as having treatment failure.
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11 subsequently taking the reduced dose of 300 mg 
per day; of the 16 patients who received 300 mg 
per day, 11 (69%) had an adverse event related to 
the study drug. A Cox proportional-hazards anal-
ysis showed that, after the second randomization, 
the group receiving the 600-mg dose was 2.7 times 
(95% confidence interval, 1.1 to 6.5) as likely to 
have an adverse event as the group receiving the 
300-mg dose (P = 0.03) (Fig. 3B, and Fig. 3 in the 
Supplementary Appendix).
DRUG RESISTANCE
Of the four patients who did not have a response 
to treatment, three (two in the 300-mg group, and 
one in the 600-mg group) did not have confirmed 
culture conversion; the sputum smears and cul-
tures for these three patients improved initially, 
but they did not have a consistent negative-culture 
status and were classified as having treatment 
failure rather than treatment relapse. The fourth 
patient, who was in the 600-mg group, had a 
treatment relapse (cultures became negative but 
turned positive again after 1 year of treatment).
The minimum inhibitory concentration of the 
corresponding isolates for these four patients in-
creased by a factor of 8 to a factor of 32, as com-
pared with baseline (Fig. 4A). DNA sequencing 
of these isolates revealed mutations, either in 23S 
Table 1. Baseline Characteristics of the Study Participants According to Treatment Group.*
Characteristic
Immediate-Start 
Group  
(N = 19)
Delayed-Start Group
(N = 20)
Total
(N = 39)
Age — yr
Mean 42.1 40.4 41.2
Range 20–64 23–63 20–64
Male sex — no. (%) 12 (63) 16 (80) 28 (72)
Body-mass index†
Mean 19.6 20.5 20.0
Range 14.9–25.7 14.4–28.1 14.4–28.1
Diabetes mellitus — no. (%) 7 (37) 7 (35) 14 (36)
BCG vaccination scar — no. (%) 14 (74) 17 (85) 31 (79)
Radiographic findings — no. (%)
Far advanced tuberculosis‡ 15 (79) 15 (75) 30 (77)
Cavitary tuberculosis 9 (47) 8 (40) 17 (44)
Bilateral lesions 18 (95) 20 (100) 38 (97)
No. of previous treatment episodes for tuberculosis
Median 5.0 5.0 5.0
Interquartile range 3.0–8.5 4.0–7.0 3.0–7.3
No. of resistant drugs§
Mean 11.6 10.4 11.0
Range 8–15 6–14 6–15
* There were no significant between-group differences. BCG denotes bacille Calmette–Guérin.
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡ Far advanced tuberculosis was defined according to the guidelines of the Korea Centers for Disease Control and 
Prevention26 as the presence of disseminated lesions of slight-to-moderate density exceeding the total volume of one 
lung, or dense and confluent lesions exceeding one third the volume of one lung, or the presence of cavities greater 
than 4 cm in diameter.
§  Drug-susceptibility testing for 15 drugs was performed: isoniazid, para-aminosalicylic acid, streptomycin, ethambutol, 
rifampin, protionamide, cycloserine, kanamycin, amikacin, ofloxacin, levofloxacin, pyrazinamide, rifabutin, moxifloxacin, 
and capreomycin.
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rRNA or in the ribosomal protein L3, in all four 
patients (Fig. 4A). The observed mutations have 
previously been reported in association with lin-
ezolid resistance from M. smegmatis29 and M. tu-
berculosis.30,31
PHARMACOKINETICS
The maximal and minimal plasma concentra-
tions that we observed for linezolid (Fig. 4B) are 
generally in agreement with published pharma-
cokinetic data in patients with other infectious 
diseases.22,32,33 Considering that the plasma pro-
tein binding of linezolid is approximately 30%, 
plasma levels of free linezolid were above the 
measured minimum inhibitory concentration for 
each isolate during the entire dosing interval in 
almost all patients taking 600 mg per day. Among 
those taking 300 mg per day, the trough level 
was lower than the mean minimum inhibitory 
concentration in nine patients, including the two 
in whom linezolid resistance developed during 
treatment with that dose. The two doses provided 
proportional exposures, with a mean (±SD) area 
under the curve of 180.4±89 μg per milliliter per 
hour for the 600-mg dose and 91.1±43 μg per 
milliliter per hour for the 300-mg dose. Using 
Cox regression, we found no association between 
the time to culture conversion (measured from the 
date of the start of treatment with linezolid) and 
either the peak level (P = 0.93) or the trough level 
(P = 0.92), measured after at least 2 weeks of lin-
ezolid treatment.
DISCUSSION
In this analysis involving 39 patients with XDR pul-
monary tuberculosis who had not had a response 
to any standard treatment regimen for 6 months 
or more, we found that the immediate addition of 
linezolid at a dose of 600 mg per day to the ongo-
ing background treatment regimen had a signifi-
cant beneficial effect on the time to sputum-culture 
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Figure 2. Kaplan–Meier Curves for Culture Conversion 
According to Time since Randomization.
Panel A shows the results for solid culture medium, 
and Panel B the results for liquid culture medium. In 
both panels, the gray vertical lines indicate the start of 
treatment (at 2 months) in the delayed-treatment 
group and the time of data censoring (at 4 months). 
Panel C shows the time to culture conversion on solid 
medium (solid line) along with the 95% confidence inter-
val (dashed lines) for the 38 participants who received 
linezolid, according to the duration of linezolid therapy. 
Tick marks indicate the censored observations at the 
time of the last follow-up visit with culture results.
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conversion on solid medium, as compared with 
the delayed addition of linezolid at the same dose. 
During the first 6 months of treatment, 34 of the 
39 patients (87%) had confirmed culture conver-
sion, at a median of 76 days.
In studies conducted immediately after the dis-
covery of streptomycin, which is also a protein-
synthesis inhibitor, the rate of culture conversion 
at 3 months was only 19%,34 whereas in the pres-
ent study, 60% of patients who received linezolid 
had negative sputum cultures at 3 months. Mono-
therapy with isoniazid was also studied through-
out the 1950s, and in those studies, less than 32% 
of patients had sputum-culture conversion during 
the first 3 months of treatment.35 First-line qua-
druple drug therapy (isoniazid, rifampin, pyra-
zinamide, and ethambutol) has been associated 
with a mean time to culture conversion on solid 
medium of 30 to 40 days.36,37 In patients with 
MDR tuberculosis who were treated with second-
line agents, the conversion rate was substantially 
lower, and the time to conversion was longer. For 
example, in a recent study that used a five-drug 
regimen (kanamycin, ofloxacin, ethionamide, pyr-
azinamide, and cycloserine), less than 10% of pa-
tients had a negative culture after 2 months.38 In 
larger studies involving patients with MDR tuber-
culosis, the estimated median time to culture 
conversion was 63 days.39 Linezolid alone would 
therefore appear to be similar to the five-drug 
chemotherapy regimen currently used as second-
line treatment, and the incorporation of linezolid 
into second-line regimens may substantially im-
prove culture-conversion rates.
A major concern in undertaking this trial was 
the emergence of acquired resistance to linezolid 
because we were adding a single active drug to a 
failing regimen. In early studies of streptomycin as 
monotherapy, 35 of 41 patients (85%) had resistant 
organisms at a mean of 53 days after the initiation 
of therapy.34 Likewise, by 3 months, resistant ba-
cilli developed in 83% of the patients who received 
isoniazid monotherapy.35 In our study, 4 of the 
38 patients who received linezolid for 6 months 
or more (11%) had apparent acquired resistance. 
This low frequency of acquisition of resistance may 
be related to the low rate of observed mutation to 
linezolid resistance in vitro (estimated at 10−9).30 
The dose of 600 mg per day also maintained lin-
ezolid levels above the published mutant-preven-
tion concentration of 0.6 μg per milliliter40 and 
may have played a role in reducing the incidence 
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Figure 3. Probability of Event-free Survival over Time.
The Kaplan–Meier curves in Panel A show the time to the onset of clinically 
significant adverse events that resulted in a drug holiday or dose adjustment 
during the study. Symbols indicate data-censoring points for patients remain-
ing in the study (see Table 3 in the Supplementary Appendix for detailed risk 
estimates corrected for person-years of exposure). The curves in Panel B 
show the time to the first adverse event in patients after the second random-
ization to either a continuation of the 600-mg daily dose or a reduced dose 
of 300 mg per day. Tick marks indicate data-censoring points for individual 
patients who continued to receive the study drug.
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of acquired resistance. The relatively small num-
ber of clinical isolates with reported linezolid 
resistance is consistent with this observation.41
The significant beneficial effect of linezolid 
was tempered, as expected, by the high rates of 
drug-related adverse events, although almost all 
events resolved quickly with a reduction in the 
dose or the temporary cessation of linezolid, and 
only three patients discontinued the study owing 
to adverse events. As we also expected, adverse 
events were significantly reduced in patients 
who subsequently received the reduced dose of 
300 mg per day. The pharmacokinetic profile of 
the 300-mg dose, as compared with the minimum 
inhibitory concentration of the isolates, showed 
that this dose was sufficient to maintain serum 
levels above the minimum inhibitory concentra-
tion in most patients, although it is worrisome 
that three of the patients in whom resistance 
developed had relatively low exposures while 
receiving the 300-mg dose (Fig. 4B). Whether the 
lower dose, which is associated with fewer ad-
verse events, has sufficient potency will need to 
be further evaluated, along with the possible role 
of therapeutic drug monitoring. Linezolid shows 
good pulmonary penetration42,43 and has been 
shown to have favorable distribution in infected 
soft tissue.44,45 These pharmacokinetic properties 
may also play a role in maintaining linezolid con-
centrations that are high enough to prevent the 
emergence of resistant organisms.
This study is limited by the small number of 
patients evaluated, particularly the small number 
of patients who did not have a response to treat-
ment or in whom resistance developed. Although 
the small numbers of treatment failure and cases 
of acquired resistance are encouraging, they also 
preclude more in-depth analyses of the associ-
ated risk factors. Balancing the long-term risk–
benefit ratio of linezolid requires identifying a 
dose with sufficient potency but less toxicity.
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Figure 4. Resistance to and Pharmacokinetics of Linezolid.
Acquired resistance to linezolid was observed in the 
isolates from four patients; mutations in the linezolid-
binding site of the 23S ribosomal RNA (rRNA) devel-
oped in two patients, and mutations in the mycobacte-
rial ribosomal protein L3 gene (rplC) in the other two 
(Panel A). Numbers for 23S rRNA indicate the location 
of mutations according to Escherichia coli numbering. The 
pharmacokinetics of exposure to linezolid were measured 
for all patients while they were receiving 600 mg per day 
and for all patients who subsequently received 300 mg 
per day (Panel B). Plasma concentrations for the four 
patients in whom resistant organisms developed are 
shown in red, and the dose the patient was taking at the 
time of resistance detection is indicated by triangles 
(600 mg) or circles (300 mg). The minimum inhibitory 
concentration (MIC) for linezolid in the initial isolates 
from the patients and the mean MIC (horizontal line) 
are shown at the right.
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